Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein.

Sekigawa A, Fujita M, Sekiyama K, Takamatsu Y, Hatano T, Rockenstein E, La Spada AR, Masliah E, Hashimoto M.

Mol Brain. 2012 Sep 26;5:34. doi: 10.1186/1756-6606-5-34.

2.

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.

Sekigawa A, Takamatsu Y, Sekiyama K, Hashimoto M.

Biomolecules. 2015 May 19;5(2):1000-11. doi: 10.3390/biom5021000. Review.

3.

Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

Galvin JE, Uryu K, Lee VM, Trojanowski JQ.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13450-5.

4.

A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain.

Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, Waragai M, Takenouchi T, Takamatsu Y, Wei J, Rockenstein E, Laspada AR, Masliah E, Inoue S, Hashimoto M.

Nat Commun. 2010 Nov 2;1:110.

5.

Diversity of mitochondrial pathology in a mouse model of axonal degeneration in synucleinopathies.

Sekigawa A, Takamatsu Y, Sekiyama K, Takenouchi T, Sugama S, Waragai M, Fujita M, Hashimoto M.

Oxid Med Cell Longev. 2013;2013:817807. doi: 10.1155/2013/817807. Epub 2013 Mar 14. Review.

6.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
7.

Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies.

Fujita M, Sekigawa A, Sekiyama K, Takamatsu Y, Hashimoto M.

Int J Mol Sci. 2012;13(9):11584-92. doi: 10.3390/ijms130911584. Epub 2012 Sep 14. Review.

8.

Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H β-synuclein.

Sekiyama K, Fujita M, Sekigawa A, Takamatsu Y, Waragai M, Takenouchi T, Sugama S, Hashimoto M.

Neurosci Lett. 2012 Apr 25;515(1):97-101. doi: 10.1016/j.neulet.2012.03.037. Epub 2012 Mar 21.

PMID:
22459406
9.

The loss of inhibitory C-terminal conformations in disease associated P123H β-synuclein.

Janowska MK, Baum J.

Protein Sci. 2016 Jan;25(1):286-94. doi: 10.1002/pro.2798. Epub 2015 Sep 21.

PMID:
26332674
10.

Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E.

Am J Pathol. 2013 Mar;182(3):940-53. doi: 10.1016/j.ajpath.2012.11.018. Epub 2013 Jan 9.

11.

Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies.

Wei J, Fujita M, Nakai M, Waragai M, Watabe K, Akatsu H, Rockenstein E, Masliah E, Hashimoto M.

J Biol Chem. 2007 Sep 28;282(39):28904-14. Epub 2007 Jul 24.

12.

Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.

Uchihara T, Giasson BI.

Acta Neuropathol. 2016 Jan;131(1):49-73. doi: 10.1007/s00401-015-1485-1. Epub 2015 Oct 7. Review.

13.

Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein.

Israeli E, Sharon R.

J Neurochem. 2009 Jan;108(2):465-74. doi: 10.1111/j.1471-4159.2008.05776.x. Epub 2008 Dec 2.

14.

Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E.

PLoS One. 2010 Nov 16;5(11):e14020. doi: 10.1371/journal.pone.0014020.

15.

Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E.

PLoS One. 2010 Feb 19;5(2):e9313. doi: 10.1371/journal.pone.0009313.

16.

Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA.

Bétemps D, Verchère J, Brot S, Morignat E, Bousset L, Gaillard D, Lakhdar L, Melki R, Baron T.

Acta Neuropathol Commun. 2014 Mar 13;2:29. doi: 10.1186/2051-5960-2-29.

17.

[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].

Orimo S.

Rinsho Shinkeigaku. 2008 Jan;48(1):11-24. Review. Japanese.

PMID:
18386627
18.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

19.

Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein.

Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, Pfragner R, Schreiner E, Windisch M, Masliah E.

J Neurosci Res. 2005 Apr 15;80(2):247-59.

PMID:
15765523
20.

Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology.

Tsuboi Y, Uchikado H, Dickson DW.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S221-4. doi: 10.1016/S1353-8020(08)70005-1.

PMID:
18267239
Items per page

Supplemental Content

Write to the Help Desk